Bayer/Onyx Nexavar FDA Review Shows Debate Over Full Vs. Subpart H Approval
This article was originally published in Pharmaceutical Approvals Monthly
Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.
You may also be interested in...
FDA’s decision to grant Pfizer’s Sutent a broad renal cell carcinoma claim suggests a consensus among reviewers that partial responses may be predictive of clinical benefit in RCC.
Antigenics is shifting its focus to its Phase I and preclinical development programs following the failure of its therapeutic vaccine Oncophage in a Phase III renal cell carcinoma (RCC) trial, the company said
Cancer trials need new methods of measuring progression, FDA guidance says. Draft document on clinical trial endpoints for cancer drugs advocates survival as “gold standard,” but discusses value of progression assessment as potential surrogate marker